|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STK33 |
Gene summary for STK33 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STK33 | Gene ID | 65975 |
| Gene name | serine/threonine kinase 33 | |
| Gene Alias | STK33 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | B4DDH2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65975 | STK33 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 6.18e-18 | 8.85e-01 | -0.2116 |
| 65975 | STK33 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.36e-05 | 8.29e-01 | -0.1941 |
| 65975 | STK33 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 4.19e-06 | 6.92e-01 | -0.2107 |
| 65975 | STK33 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 4.00e-13 | 8.17e-01 | -0.2119 |
| 65975 | STK33 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 5.66e-06 | 3.93e-01 | -0.0166 |
| 65975 | STK33 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 7.55e-08 | 3.80e-01 | -0.0132 |
| 65975 | STK33 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 3.46e-14 | 4.82e-01 | -0.013 |
| 65975 | STK33 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.38e-06 | 3.50e-01 | -0.0121 |
| 65975 | STK33 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.99e-03 | 5.90e-01 | -0.0961 |
| 65975 | STK33 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 9.54e-04 | 5.58e-01 | -0.0876 |
| 65975 | STK33 | HTA12-15-2 | Human | Pancreas | PDAC | 6.09e-07 | 5.88e-01 | 0.2315 |
| 65975 | STK33 | HTA12-23-1 | Human | Pancreas | PDAC | 1.10e-17 | 1.14e+00 | 0.3405 |
| 65975 | STK33 | HTA12-25-1 | Human | Pancreas | PDAC | 2.67e-12 | 8.09e-01 | 0.313 |
| 65975 | STK33 | HTA12-26-1 | Human | Pancreas | PDAC | 9.45e-35 | 1.26e+00 | 0.3728 |
| 65975 | STK33 | HTA12-29-1 | Human | Pancreas | PDAC | 6.36e-65 | 1.21e+00 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00427704 | Lung | IAC | signal transduction in response to DNA damage | 45/2061 | 172/18723 | 2.06e-08 | 2.55e-06 | 45 |
| GO:00467776 | Lung | IAC | protein autophosphorylation | 51/2061 | 227/18723 | 4.85e-07 | 3.10e-05 | 51 |
| GO:19019872 | Lung | IAC | regulation of cell cycle phase transition | 69/2061 | 390/18723 | 4.55e-05 | 1.06e-03 | 69 |
| GO:00073464 | Lung | IAC | regulation of mitotic cell cycle | 78/2061 | 457/18723 | 5.37e-05 | 1.21e-03 | 78 |
| GO:00457861 | Lung | IAC | negative regulation of cell cycle | 67/2061 | 385/18723 | 9.74e-05 | 1.93e-03 | 67 |
| GO:00000773 | Lung | IAC | DNA damage checkpoint | 27/2061 | 115/18723 | 1.03e-04 | 2.02e-03 | 27 |
| GO:00447733 | Lung | IAC | mitotic DNA damage checkpoint | 21/2061 | 81/18723 | 1.34e-04 | 2.50e-03 | 21 |
| GO:00459301 | Lung | IAC | negative regulation of mitotic cell cycle | 45/2061 | 235/18723 | 1.49e-04 | 2.73e-03 | 45 |
| GO:19019881 | Lung | IAC | negative regulation of cell cycle phase transition | 47/2061 | 249/18723 | 1.53e-04 | 2.80e-03 | 47 |
| GO:00109481 | Lung | IAC | negative regulation of cell cycle process | 53/2061 | 294/18723 | 2.05e-04 | 3.58e-03 | 53 |
| GO:00447743 | Lung | IAC | mitotic DNA integrity checkpoint | 21/2061 | 85/18723 | 2.78e-04 | 4.56e-03 | 21 |
| GO:00315703 | Lung | IAC | DNA integrity checkpoint | 27/2061 | 123/18723 | 3.34e-04 | 5.24e-03 | 27 |
| GO:00000752 | Lung | IAC | cell cycle checkpoint | 33/2061 | 169/18723 | 7.51e-04 | 9.82e-03 | 33 |
| GO:00070932 | Lung | IAC | mitotic cell cycle checkpoint | 26/2061 | 129/18723 | 1.62e-03 | 1.71e-02 | 26 |
| GO:004277011 | Lung | AIS | signal transduction in response to DNA damage | 37/1849 | 172/18723 | 4.17e-06 | 2.13e-04 | 37 |
| GO:004677711 | Lung | AIS | protein autophosphorylation | 39/1849 | 227/18723 | 4.30e-04 | 7.37e-03 | 39 |
| GO:00447731 | Lung | AIS | mitotic DNA damage checkpoint | 18/1849 | 81/18723 | 7.81e-04 | 1.11e-02 | 18 |
| GO:00447741 | Lung | AIS | mitotic DNA integrity checkpoint | 18/1849 | 85/18723 | 1.41e-03 | 1.73e-02 | 18 |
| GO:000007711 | Lung | AIS | DNA damage checkpoint | 22/1849 | 115/18723 | 1.82e-03 | 2.05e-02 | 22 |
| GO:00315701 | Lung | AIS | DNA integrity checkpoint | 22/1849 | 123/18723 | 4.32e-03 | 3.86e-02 | 22 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STK33 | SNV | Missense_Mutation | c.1070N>C | p.Val357Ala | p.V357A | Q9BYT3 | protein_coding | tolerated(0.21) | benign(0.034) | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| STK33 | SNV | Missense_Mutation | novel | c.636N>T | p.Glu212Asp | p.E212D | Q9BYT3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STK33 | SNV | Missense_Mutation | novel | c.89N>A | p.Ser30Asn | p.S30N | Q9BYT3 | protein_coding | tolerated_low_confidence(1) | benign(0.018) | TCGA-AR-A2LH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| STK33 | insertion | Nonsense_Mutation | novel | c.371_372insTTGATATGTTACCTTACTAAACATT | p.Lys124AsnfsTer2 | p.K124Nfs*2 | Q9BYT3 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| STK33 | deletion | Frame_Shift_Del | novel | c.1208delA | p.Asn403IlefsTer23 | p.N403Ifs*23 | Q9BYT3 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| STK33 | SNV | Missense_Mutation | c.319N>C | p.Glu107Gln | p.E107Q | Q9BYT3 | protein_coding | tolerated(0.08) | benign(0.109) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| STK33 | SNV | Missense_Mutation | c.1523N>T | p.Ser508Phe | p.S508F | Q9BYT3 | protein_coding | tolerated_low_confidence(0.77) | benign(0.001) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| STK33 | SNV | Missense_Mutation | c.895N>A | p.Asp299Asn | p.D299N | Q9BYT3 | protein_coding | deleterious(0.02) | possibly_damaging(0.864) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STK33 | SNV | Missense_Mutation | c.1367T>G | p.Phe456Cys | p.F456C | Q9BYT3 | protein_coding | tolerated_low_confidence(0.18) | benign(0.19) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| STK33 | SNV | Missense_Mutation | c.722N>G | p.Leu241Arg | p.L241R | Q9BYT3 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3655-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 65975 | STK33 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565870 | ||
| 65975 | STK33 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |